Eosinophil and Anticoagulation in COVID-19 Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-15

Study Completion Date

2020-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of Hospitalisation Times and Mortality According to Drug Dose in Patients Given Systemic Methylprednisolone With a Pre-diagnosis of Covid-19 Pneumonia; Retrospective Study

NCT04847687

COVID-19 Methylprednisolone Pneumonia

COMPLETED

The Effect of Monocyte Values Accompanied by Lymphopenia on the Prognosis of Patients Diagnosed With COVID-19

NCT06968156

COVID 19 Lymphopenia Due to COVID-19 Monocyte

COMPLETED

Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .

NCT04105439

Behçet Disease

UNKNOWN

Annexin A1 Levels in SARS-CoV-2 Infection

NCT04948229

Annexin A1 Adrenal Cortex Hormones

COMPLETED

Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease

NCT06721234

Behçet

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID 19 positive patients

LMWH

Intervention Type DRUG

COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LMWH

COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH,
* agreed to participate in the study were included

Exclusion Criteria

* Patients with previous coagulopathy,
* continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease),
* glomerular filtration rate (GFR) \<30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No